SFX by Ex Libris Inc.

Title:	Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
Source:	Nature Genetics [1061-4036] Seki, Masafumi yr:2017

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Das, Kuntal K. "Capsuloganglionic Germinoma: A Rare Site for Uncommon Childhood Tumor." Asian Journal of Neurosurgery (2018): 492-495.
description	2.	De Bie, J. "Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia." Leukemia 32.6 (2018): 1-12.
description	3.	Nabet, B. "The dTAG system for immediate and target-specific protein degradation." Nature Chemical Biology 14.5 (2018): 431-441.
description	4.	Monoi, A. "Atypical dyskeratosis congenita diagnosed using whole-exome sequencing." Pediatrics international. 59.8: 933-935.
description	5.	Zhang, Guopeng i. "Clinical and Radiologic Features of Pediatric Basal Ganglia Germ Cell Tumors." World neurosurgery (2016): 516-5240.
description	6.	Gray, Nathanael S. "Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8." ACS Medicinal Chemistry Letters 9.6 (2018): 540-545.
description	7.	Gechijian, Lara N. "Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands." Nature Chemical Biology 14.4 (2018): 405-412.
description	8.	Quackenbush, Héctor C. "Smooth quantile normalization." Biostatistics 19.2 (2018): 185-198.
description	9.	Kato, M. "Genomic analysis of clonal origin of Langerhans cell histiocytosis following acute lymphoblastic leukaemia." British journal of haematology (2015): 169-172.
description	10.	Deshaies, Raymond J. "Protein degradation: Prime time for PROTACs." Nature Chemical Biology 11.9 (2015): 634-5.
description	11.	Bradner, James E. "Phthalimide conjugation as a strategy for in vivo target protein degradation." Science 348.6241 (2015): 1376-1381.
description	12.	Bondeson, Daniel P P. "Catalytic in vivo protein knockdown by small-molecule PROTACs." Nature Chemical Biology 11.8 (2015): 611-7.
description	13.	Ferguson, Fleur M. "Kinase inhibitors: the road ahead." Nature reviews. Drug discovery 17.5 (2018): 353-377.
description	14.	Farnaby, W. "BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design." Nature chemical biology. 15.7: 672-680.
description	15.	"Oncology - Neuroblastomas; Investigators from Baylor University College of Medicine Have Reported New Data on Neuroblastomas (Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma)." Obesity, fitness, & wellness week. 1649-.
description	16.	Sahni, Jennifer M. "Targeting bromodomain and extraterminal proteins in breast cancer." Pharmacological research 129 (2018): 156-176.
description	17.	Signer, M. "Living Up to the Hype: Protein Synthesis Promotes Hypertranscription in Embryonic Stem Cells." Cell stem cell 22.3 (2018): 281-282.
description	18.	Jiang, S. "Clinical features, radiologic findings, and treatment of pediatric germ cell tumors involving the basal ganglia and thalamus: a retrospective series of 15 cases at a single center." Child's Nervous System (2017): 423-430.
description	19.	Buckley, Dennis L. "HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins." ACS chemical biology 10.8 (2015): 1831-7.
description	20.	Ciceri, P. "Dual kinase-bromodomain inhibitors for rationally designed polypharmacology." Nature chemical biology 10.4 (2014): 305-312.